{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:38:42Z","timestamp":1783996722397,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jiac.2021.12.022","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T06:27:54Z","timestamp":1641796074000},"page":"465-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-231X","authenticated-orcid":false,"given":"Hannah","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-1013","authenticated-orcid":false,"given":"Abhimanyu","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-4918","authenticated-orcid":false,"given":"Jennifer","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2021.12.022_bib1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.jiac.2021.12.022_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \"lineless antibiotics\" for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2021.12.022_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jiac.2021.12.022_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient Antibiotic therapy","volume":"7","author":"Vazquez Deida","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2021.12.022_bib5","series-title":"Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. NCHS Data Brief, no 360","author":"Hales","year":"2020"},{"issue":"9","key":"10.1016\/j.jiac.2021.12.022_bib6","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.clinthera.2016.07.094","article-title":"Anti-infective dosing for obese adult patients: a focus on newer drugs to treat methicillin-resistant Staphylococcus aureus acute bacterial skin and skin structure infections","volume":"38","author":"Pai","year":"2016","journal-title":"Clin Therapeut"},{"issue":"3","key":"10.1016\/j.jiac.2021.12.022_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2021.12.022_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jiac.2021.12.022_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2021.12.022_bib10","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/ofid\/ofx163.114","article-title":"Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in the obese population","volume":"4","author":"Georgiades","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jiac.2021.12.022_bib11","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.01453-12","article-title":"Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults","volume":"57","author":"Bhalodi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.12.022_bib12","doi-asserted-by":"crossref","first-page":"212559","DOI":"10.7573\/dic.212559","article-title":"Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs","volume":"7","author":"Gonzalez","year":"2018","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/j.jiac.2021.12.022_bib13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/AAC.36.5.1109","article-title":"Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia","volume":"36","author":"Rybak","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2021.12.022_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.35.4.696","article-title":"Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis","volume":"35","author":"Rybak","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jiac.2021.12.022_bib15","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.34.5.792","article-title":"Vancomycin pharmacokinetics in burn patients and intravenous drug abusers","volume":"34","author":"Rybak","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2021.12.022_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1128\/AAC.27.3.285","article-title":"Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs","volume":"27","author":"King","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2021.12.022_bib17","article-title":"Evaluation of vancomycin dosing in intravenous drug users admitted to an internal medicine service","volume":"4","author":"Ferreira","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.jiac.2021.12.022_bib18","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/cid\/ciy941","article-title":"Dalbavancin dosage","volume":"68","author":"Tobudic","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2021.12.022_bib19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jiac.2021.12.022_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jiac.2021.12.022_bib21","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor's new clothes: PRospective observational evaluation of the association between initial VancomycIn exposure and failure rates among ADult HospitalizEd patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jiac.2021.12.022_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jiac.2021.12.022_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/314712","article-title":"Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients","volume":"179","author":"Fowler","year":"1999","journal-title":"J Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21003585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21003585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:03:18Z","timestamp":1761159798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21003585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1341321X21003585"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.12.022","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}